Across TCGA pan-cancer cohorts, CCDC191 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCDC191 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher CCDC191 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC191 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.
SCLC, CESC, and UCEC are the cancer types where CCDC191 Mutation most reproducibly stratifies survival.